title: Influence of aluminum-based adjuvant on the immune response to multiantigenic formulation.
abstract: Several adjuvants have been described and tested in humans. However, the aluminum-based adjuvants remain the most widely used component in vaccines today. Emerging data suggest that aluminum phosphate and aluminum hydroxide adjuvants do not promote a strong commitment to the helper T cell type 2 (Th2) pathway when they are coadministered with some Th1 adjuvants. In this regard, subtle differences between both aluminum-based adjuvants have been demonstrated. We have previously shown that subcutaneous immunization, in aluminum phosphate, of a mixture comprising the surface and core antigens of hepatitis B virus (HBV) and the multiepitopic protein CR3 of human immunodeficiency virus type 1 elicits a CR3-specific Th1 immune response. In these experiments, the antigens were adjuvated at the same time. As the final selection of the best adjuvant should be based on experimental evidence, we asked whether aluminum hydroxide allows a better Th1 immune deviation than aluminum phosphate. We also studied several ways to mix the antigens and the impact on CR3-specific interferon (IFN)-gamma secretion. Our findings indicate that aluminum hydroxide allows better Th1 immunodeviation than aluminum phosphate adjuvant for the mixture of HBV antigens and CR3. In addition, CR3-specific IFN-gamma secretion of the various formulations tested was the same irrespective of the order in which the antigens were combined.
authors.affiliation: Centro de Ingeniería Genética y Biotecnología, Havana, Cuba. enrique.iglesias@cigb.edu.cu
authors.forename: Enrique
authors.initials: E
authors.lastname: Iglesias
authors.forename: Orisley
authors.initials: O
authors.lastname: Franch
authors.forename: Yamilka
authors.initials: Y
authors.lastname: Carrazana
authors.forename: Yadira
authors.initials: Y
authors.lastname: Lobaina
authors.forename: Daymir
authors.initials: D
authors.lastname: García
authors.forename: Jorge
authors.initials: J
authors.lastname: Sanchez
authors.forename: José
authors.initials: J
authors.lastname: García
authors.forename: Dioslaida
authors.initials: D
authors.lastname: Urquiza
authors.forename: Verena
authors.initials: V
authors.lastname: Muzio
authors.forename: Gerardo
authors.initials: G
authors.lastname: Guillén
authors.forename: Julio C
authors.initials: JC
authors.lastname: Aguilar
mesh_terms: D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds / Q000276:immunology; D000536:Aluminum Hydroxide / Q000276:immunology*; D000818:Animals; D005260:Female; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology; D015488:HIV Antigens / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood / Q000276:immunology; D006512:Hepatitis B Core Antigens / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007115:Immunization Schedule; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010710:Phosphates / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology; D013045:Species Specificity; D013154:Spleen / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds; D015483:HIV Antibodies; D015488:HIV Antigens; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D010710:Phosphates; D011994:Recombinant Proteins; D000536:Aluminum Hydroxide; D007371:Interferon-gamma; C012714:aluminum phosphate